Feature|Articles|August 24, 2026

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

In the first part of a two-part series, Carre reviews of the tau and TREM2 approaches reshaping Alzheimer's drug development, with key findings from AAIC 2026 in London.

A new chapter in Alzheimer’s treatment has begun. For the first time, a therapeutic mechanism beyond amyloid has shown signs that it may meaningfully alter disease progression. Yet the limitations of the latest clinical advances also underline how much remains unresolved before Alzheimer’s can be treated effectively, safely and practically over the long term.